Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Introduction By inhibiting apolipoprotein B (ApoB) synthesis, mipomersen can significantly reduce ApoB-containing lipoproteins in hypercholesterolemic patients.Objective This study sought to ascertain both the extent to which mipomersen can decrease ApoB-containing lipoproteins and the safety of mipomersen therapy.Methods Studies were identified through PubMed, CENTRAL, Embase, Clinical Trials, reviews, and reference lists of relevant papers. The efficacy endpoints were the changes in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), ApoB, and lipoprotein (a) [Lp(a)]. The safety endpoints were the incidence of injection-site reactions, flu-like symptoms, and elevated transaminases.Results Six randomized controlled trials with 444 patients were included in the analysis. Compared with the placebo group, patients who received mipomersen therapy had a significant reduction in LDL-C (33.13%), as well as a reduction in non-HDL-C (31.70%), ApoB (33.27%), and LP(a) (26.34%). Mipomersen therapy was also associated with an obvious increase in injection-site reactions with an odds ratio (OR) of 14.15, flu-like symptoms with an OR of 2.07, and alanine aminotransferase levels ≥ 3 × the upper limit of normal with an OR of 11.21.Conclusions Mipomersen therapy is effective for lowering ApoB-containing lipoproteins in patients with severe hypercholesterolemia. Future studies exploring how to minimize side effects of mipomersen therapy are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While recent investigations have attempted to unravel the mechanism, it remains unclear. However, it appears to be distinct from that of statins, which also enhance LDLR function but do not lower circulating Lp(a) levels in humans.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [288]
In the citing paper
“In contrast to statins, inhibiting PCSK9 with mAbs also reduces Lp(a) plasma levels. Pooled results of phase II trials have shown that treatment leads to an Lp(a) reduction of about 30-40% [288,289].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [288]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Heterogeneity of effects was assessed with Chi-squared tests and I(2); an I(2)[50 % was considered to indicate significant heterogeneity between the trials [17].”
MethodGrundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807 · cited 1×
“disease [35–39] and are also the targets of lipid-lowering therapy [24].”
BackgroundRaal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924 · cited 3×
“[18], 2010 RCT Multicenter 51 HoFH Maximally tolerated lipidlowering therapy 26 weeks”
BackgroundInfluentialSniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659 · cited 1×
“disease [35–39] and are also the targets of lipid-lowering therapy [24].”
BackgroundA review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia
Marks, D., Thorogood, M., Neil, H. A. W., & Humphries, S. E. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00330-1 · Cited by 570 · cited 1×
“However, a substantial proportion of patients remain unable to achieve an optimal LDL-C concentration despite maximally tolerated lipid-lowering therapy [26–28].”
BackgroundStudy of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558 · cited 1×
“Moreover, the number of statin-intolerant patients is rising, which is manifested by the use of higher statin doses to achieve more stringent LDL-C targets [1, 29].”
BackgroundBARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 464 · cited 1×
“Apolipoprotein B (ApoB), which is produced in the liver, is an essential component of LDL-C and all other atherogenic lipoproteins [5, 6].”
BackgroundRobinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368 · cited 1×
“disease [35–39] and are also the targets of lipid-lowering therapy [24].”
BackgroundKastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 358 · cited 1×
“once weekly for 26 weeks to achieve a steady state level [10].”
BackgroundApolipoprotein B: mRNA Editing, Lipoprotein Assembly, and Presecretory Degradation
Davidson, N. O., & Shelness, G. S. (2000) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.20.1.169 · Cited by 311 · cited 1×
“Apolipoprotein B (ApoB), which is produced in the liver, is an essential component of LDL-C and all other atherogenic lipoproteins [5, 6].”
BackgroundGrundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000038419.53000.d6 · Cited by 309 · cited 1×
“disease [35–39] and are also the targets of lipid-lowering therapy [24].”
BackgroundStein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 301 · cited 3×
“[20], 2012 RCT Multicenter 124 HeFH and CHD Maximally tolerated statin therapy 26 weeks”
BackgroundInfluentialBennet, A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.598 · Cited by 281 · cited 1×
“disease [35–39] and are also the targets of lipid-lowering therapy [24].”
BackgroundDavidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270 · cited 1×
“However, a substantial proportion of patients remain unable to achieve an optimal LDL-C concentration despite maximally tolerated lipid-lowering therapy [26–28].”
BackgroundThomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245 · cited 4×
“[23], 2013 123/123 152/152 117/116 36/31”
BackgroundInfluentialYu, R. Z., Kim, T.-W., Hong, A., Watanabe, T. A., Gaus, H. J., & Geary, R. S. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012401 · Cited by 244
McGowan, M. P., Tardif, J.-C., Ceska, R., Burgess, L. J., Soran, H., Gouni-Berthold, I., Wagener, G., & Chasan-Taber, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049006 · Cited by 224 · cited 4×
“[21], 2012 276/249 305/278 202/183 61/32”
BackgroundInfluentialVisser, M. E., Wagener, G., Baker, B. F., Geary, R. S., Donovan, J. M., Beuers, U. H. W., Nederveen, A. J., Verheij, J., Trip, M. D., Basart, D. C. G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs023 · Cited by 192
Akdim, F., Visser, M. E., Tribble, D. L., Baker, B. F., Stroes, E. S. G., Yu, R., Flaim, J. D., Su, J., Stein, E. A., & Kastelein, J. J. P. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.01.003 · Cited by 179 · cited 2×
“excluded: one (lack of control group), one (investigated a different endpoint), one (duplicate report), three (ongoing studies), and four (mipomersen dose-escalation studies) [10–13].”
BackgroundAkdim, F., Stroes, E. S. G., Sijbrands, E. J. G., Tribble, D. L., Trip, M. D., Jukema, J. W., Flaim, J. D., Su, J., Yu, R., Baker, B. F., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.069 · Cited by 162 · cited 2×
“excluded: one (lack of control group), one (investigated a different endpoint), one (duplicate report), three (ongoing studies), and four (mipomersen dose-escalation studies) [10–13].”
BackgroundStein, E., Stender, S., Mata, P., Sager, P., Ponsonnet, D., Melani, L., Lipka, L., Suresh, R., MacCubbin, D., & Veltri, E. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.052 · Cited by 160
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
Akdim, F., Tribble, D. L., Flaim, J. D., Yu, R., Su, J., Geary, R. S., Baker, B. F., Fuhr, R., Wedel, M. K., & Kastelein, J. J. P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr148 · Cited by 125 · cited 2×
“excluded: one (lack of control group), one (investigated a different endpoint), one (duplicate report), three (ongoing studies), and four (mipomersen dose-escalation studies) [10–13].”
BackgroundVisser, M. E., Akdim, F., Tribble, D. L., Nederveen, A. J., Kwoh, T. J., Kastelein, J. J. P., Trip, M. D., & Stroes, E. S. G. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002915 · Cited by 113
Ballantyne, C. M., Raichlen, J. S., & Cain, V. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.052 · Cited by 111
Holmes, D. T., Schick, B. A., Humphries, K. H., & Frohlich, J. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.055228 · Cited by 73 · cited 1×
“agents have virtually no impact on Lp(a) [34].”
BackgroundMipomersen and other therapies for the treatment of severe familial hypercholesterolemia
Burnett, J., Bell, Hooper, & Watts (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28581 · Cited by 64 · cited 2×
“These include inhibitors of PCSK9, microsomal triglyceride transfer protein, and cholesteryl ester transfer protein, as well as mipomersen, the focus of this meta-analysis [30].”
BackgroundRodríguez, J. A., Grau, A., Eguinoa, E., Nespereira, B., Perez-Ilzarbe, M., Arias, R., Belzunce, M., Páramo, J. A., & Martínez-Caro, D. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00188-0 · Cited by 48 · cited 3×
“2.3 Risk of Bias Assessment To assess the risk of bias in included studies, we followed the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0), and its recommended ‘‘risk of bias’’ assessment tool for RCTs [16].”
InfluentialCombination therapy in cholesterol reduction: focus on ezetimibe and statins
Catapano, A. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1204 · Cited by 40 · cited 1×
“However, conventional lipid-lowering therapies such as statins often result in insufficient LDL-C reduction, even when administered at maximally tolerated doses [4].”
BackgroundAntisense therapy and emerging applications for the management of dyslipidemia
Toth, P. P. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.007 · Cited by 32
Gaffney, D., Forster, L. F., CASLAKE, M. J., Bedford, D. K., Stewart, J., Stewart, G., Wieringa, G. E., Dominiczak, M. H., Miller, J. P., & Packard, C. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00679-7 · Cited by 32 · cited 1×
“target levels for LDL-C in subjects with hypercholesterolemia [7].”
BackgroundStein, E. A., Ose, L., Retterstøl, K., Tonstad, S., Schleman, M. M., Harris, S., & Sager, P. T. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.07.003 · Cited by 31
Bays, H. E., Conard, S. E., Leiter, L. A., Bird, S. R., Lowe, R. S., & Tershakovec, A. M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.043 · Cited by 19 · cited 1×
“In contrast, other commonly used LDL-Creducing agents, such as statins, ezetimibe, and bile acid sequestrants, decrease the levels of ApoB and Lp(a) less significantly than LDL-C [28, 31–33].”
Result
Research works printed but not linked: 1
- Genzyme and Isis provide update on CHMP opinion on KYNAMRO™ (mipomersen). Press release, Genyzme and Isis Pharmaceuticals. http://en.sanofi.com/Images/31557_20121214_KYNAMRO_en.pdf . Accessed 15 Nov 2013.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Reactions at the injection site are the most common adverse effects observed in patients treated with mipomersen.(304) However, the main concerns regarding mipomersen’s safety are related to liver toxicity.”
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
“The Friedewald equation, which is subject to inaccuracy in the presence of high triglycerides and other conditions like diabetes, estimates LDL-C as total cholesterol minus HDL-C and very-low-density cholesterol (VLDL-C), with VLDL-C estimated as triglycerides divided by a fixed factor of Metabolites 2021, 11, 690 6 o…”
BackgroundInfluentialFamilial hypercholesterolemia treatments: Guidelines and new therapies
Raal, F. J., Hovingh, G. K., & Catapano, A. L. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.859 · Cited by 194
Metadata
- Authors
- Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2014-06-11
- Volume
- 14
- Issue
- 5
- Pages
- 367-376
- ISSN
- 1175-3277 (ISSN-L)
- 1179-187X
- OpenAlex
- W2133781918
- Cited by
- 45
- References
- 40
- Citations by year
- 2024: 6 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 2
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- mipomersen, hypercholesterolemia, apolipoprotein B, LDL cholesterol, non-HDL cholesterol, lipoprotein(a), apolipoprotein B-containing lipoproteins, drug safety, injection site reactions, flu-like symptoms, elevated liver enzymes, PCSK9 inhibition
- MeSH terms
- Adult, Anticholesteremic Agents, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Oligonucleotides, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.